GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (LTS:0MR5) » Definitions » Price-to-Owner-Earnings

CellaVision AB (LTS:0MR5) Price-to-Owner-Earnings : 49.28 (As of May. 30, 2024)


View and export this data going back to 2016. Start your Free Trial

What is CellaVision AB Price-to-Owner-Earnings?

As of today (2024-05-30), CellaVision AB's share price is kr272.50. CellaVision AB's Owner Earnings per Share (TTM) ended in Mar. 2024 was kr5.53. It's Price-to-Owner-Earnings for today is 49.28.


The historical rank and industry rank for CellaVision AB's Price-to-Owner-Earnings or its related term are showing as below:

LTS:0MR5' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.6   Med: 93.05   Max: 3027.78
Current: 46.09

During the past 13 years, the highest Price-to-Owner-Earnings of CellaVision AB was 3027.78. The lowest was 17.60. And the median was 93.05.


LTS:0MR5's Price-to-Owner-Earnings is ranked worse than
65.96% of 282 companies
in the Medical Devices & Instruments industry
Industry Median: 32.895 vs LTS:0MR5: 46.09

As of today (2024-05-30), CellaVision AB's share price is kr272.50. CellaVision AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr5.92. Therefore, CellaVision AB's PE Ratio for today is 46.03.

As of today (2024-05-30), CellaVision AB's share price is kr272.50. CellaVision AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr5.92. Therefore, CellaVision AB's PE Ratio without NRI for today is 46.03.

During the past 13 years, CellaVision AB's highest PE Ratio without NRI was 136.46. The lowest was 16.38. And the median was 51.08.


CellaVision AB Price-to-Owner-Earnings Historical Data

The historical data trend for CellaVision AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Price-to-Owner-Earnings Chart

CellaVision AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 224.89 97.88 113.52 56.88

CellaVision AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 232.38 920.00 72.59 56.88 43.34

Competitive Comparison of CellaVision AB's Price-to-Owner-Earnings

For the Medical Devices subindustry, CellaVision AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Price-to-Owner-Earnings falls into.



CellaVision AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CellaVision AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=272.50/5.53
=49.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellaVision AB  (LTS:0MR5) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CellaVision AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB (LTS:0MR5) Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers.

CellaVision AB (LTS:0MR5) Headlines

No Headlines